Julie Burek - Mar 21, 2022 Form 4 Insider Report for Voyager Therapeutics, Inc. (VYGR)

Signature
/s/ Robert Hesslein, as Attorney-in-Fact for Julie Burek
Stock symbol
VYGR
Transactions as of
Mar 21, 2022
Transactions value $
-$21,972
Form type
4
Date filed
3/23/2022, 06:36 PM
Previous filing
Feb 22, 2022

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction VYGR Common Stock Sale -$21.7K -2.62K -4.75% $8.29 52.5K Mar 21, 2022 Direct F1, F2
transaction VYGR Common Stock Sale -$269 -31 -0.06% $8.68 52.5K Mar 21, 2022 Direct F1, F3
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Represents shares of common stock sold, pursuant to a durable automatic sales instruction letter effecting the sell-to-cover election of the reporting person to satisfy tax withholding obligations, in connection with the vesting of restricted stock units on March 19, 2022. The reporting person structured the durable automatic sales instructions to constitute a "binding contract" consistent with the affirmative defense to liability under Rule 10b5-1. The sales do not represent a discretionary trade by the reporting person.
F2 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $7.66 to $8.655, inclusive. The reporting person undertakes to provide to Voyager Therapeutics, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote (2) to this Form 4.
F3 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $8.66 to $8.695, inclusive. The reporting person undertakes to provide to Voyager Therapeutics, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnote (3) to this Form 4.